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monozygotic and dizygotic twins (average age 32) who 
were assessed on CUD and MDD using the SSAGA-OZ 
interview. Data were analyzed in OpenMx. Of the 13 dif-
ferent co-morbidity models, two fit equally well: CUD 
causes MDD and Random Multiformity of CUD. Both fit 
substantially better than the Correlated Liabilities model. 
Although the current study cannot differentiate between 
them statistically, these models, in combination, suggest 
that CUD risk factors may causally influence the risk to 
develop MDD, but only when risk for CUD is high.
Keywords Co-morbidity · Major depressive disorder · 
Cannabis use disorder · Twin model · Genetics
Introduction
Major depressive disorder (MDD) and Cannabis use disor-
der (CUD) are co-morbid (see Degenhardt et al. 2012) and 
highly relevant from a public health perspective. Accord-
ing to the latest Global Burden of Disease study in 2013, 
MDD was the 2nd leading cause of disability in the world 
(Ferrari et  al. 2013), and the World Health Organization 
is now citing it as the leading one (WHO 2016). Heavy 
cannabis use is linked to several adverse health outcomes 
(Hall and Degenhardt 2009; Hall 2015), and is the most 
commonly used illicit drug (Agrawal and Lynskey 2014). 
The relationship between MDD and CUD is poorly under-
stood, although individuals with co-morbid mental health 
and substance use disorders are particularly difficult to treat 
(Kessler 2004). Developing a greater understanding of the 
relationship between CUD and MDD is therefore important 
in order to help reduce the prevalence of both conditions 
through the efficient prevention and treatment of co-morbid 
cases.
Abstract Cannabis use disorder (CUD) co-occurs with 
major depressive disorder (MDD) more frequently than 
would be expected by chance. However, studies to date 
have not produced a clear understanding of the mechanisms 
underlying this co-morbidity. Genetically informative stud-
ies can add valuable insight to this problem, as they allow 
the evaluation of competing models of co-morbidity. This 
study uses data from the Australian Twin Registry to com-
pare 13 co-morbidity twin models initially proposed by 
Neale and Kendler (Am J Hum Genet 57:935–953, 1995). 
The analysis sample comprised 2410 male and female 
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Cross-sectional studies of general and clinical popula-
tions consistently show that CUD and MDD co-occur at a 
rate greater than chance (see Degenhardt et al. 2012 for a 
review). For instance, an epidemiological study of 43,093 
US citizens showed that individuals with mood disorders 
(MDD, dysthymia, mania, hypomania) had 3.9 (95% CI 
2.8–5.3) times higher odds of meeting criteria for lifetime 
cannabis abuse and dependence (Martins and Gorelick 
2011). An epidemiological survey of 25,113 Canadian citi-
zens reported that rates of past-year cannabis dependence 
among individuals who met 12 month MDD criteria were 
over 7.25 times higher compared to those who did not (Pat-
ten et al. 2015). Rates of past-year abuse were almost 3.6 
times higher (Patten et al. 2015). Similar results have been 
found in clinical samples. For example, a recent study based 
on the Norwegian patient registry including 2,659,966 indi-
viduals, reported that levels of ICD-10 depressive illness 
were almost 3.9 times higher among individuals with CUD 
(12.85%), compared to the general population (3.3%, Nes-
våg et al. 2015).
There have been several attempts, including longitudinal 
and genetic studies, to explain this pattern of co-morbidity. 
Most longitudinal studies have looked at the relationship 
between MDD and cannabis use, rather than CUD. Stud-
ies investigating non-heavy cannabis use have not been able 
to establish a clear causal link in either direction (e.g. Lev-
Ran et al. 2014; Feingold et al. 2014; Cougle et al. 2015; 
Danielsson et  al. 2016). However, heavy cannabis use is 
more consistently and more strongly associated with MDD. 
In a meta-analysis Lev-Ran et al. (2014) found a moderate 
(OR 1.62, 95% CI 1.21–2.16) increase in risk of develop-
ing depressive disorders following heavy cannabis use. The 
strongest statistically significant relationships have been 
observed between clinical levels of cannabis use and MDD, 
with cannabis abuse preceding MDD (OR 4.00, 95% CI 
1.23–12.99, Bovasso 2001) and CUD preceding MDD (OR 
2.54, 95% CI 1.40–4.60, Marmorstein et  al. 2012). How-
ever, there is also some evidence of a bidirectional rela-
tionship, from baseline CUD to incident MDD (OR 1.78, 
95% CI 1.17–2.71), as well as baseline MDD to incident 
CUD (OR 2.28, 95% CI 1.28–4.05; Pacek et  al. 2013), 
while other studies have found no significant relationships 
(Harder et al. 2008; Feingold et al. 2014).
Overall, causal influences, mainly from CUD to MDD, 
may be present, but clear conclusions are precluded by 
the heterogeneity among studies, particularly in terms of 
the control for confounding factors. Feingold et al. (2014) 
found that cannabis users and non-users differed signifi-
cantly on age, gender, household income and marital sta-
tus. An early study by Fergusson and Horwood (1997) also 
demonstrated differences on a large number of factors, 
including childhood adversities, social disadvantage, con-
tact with peers who engaged in substance use or delinquent 
behaviors, and psychological adjustment problems. Estab-
lishing causality in either direction therefore still requires 
further evidence.
Previous twin studies investigating this co-morbidity 
have been scarce, and offered mixed evidence. In a discord-
ant twin study by Lynskey et  al. (2004), there was a sig-
nificant genetic correlation between cannabis dependence 
and MDD (men, r = 0.44, 95% CI = 0.17–1.00; women, 
r = 0.69, 95% CI 0.30–1.00), but cannabis dependence was 
not a unique causal factor for MDD. Among MZ twins 
discordant for cannabis dependence, the dependent twins 
did not have greater odds for MDD (OR 1.16, 95% CI 
0.64–2.17). Lynskey et  al. (2004) also found no evidence 
of causality in the opposite direction (OR 1.38, 95% CI 
0.55–3.42). In contrast, Lin et al. (1996) reported that MZ 
twins with MDD were more likely to be cannabis depend-
ent (OR 2.3, 95% CI 1.1–4.7), compared to their co-twins 
without MDD. Differences in results between these stud-
ies might be explained by differences in their samples. Lin 
et  al.’s (1996) analysis sample, i.e. twins discordant for 
lifetime MDD, comprised 234 male veterans twin pairs, 
while Lynskey et al. (2004) examined a sample of 156 twin 
pairs from the general population, including both male and 
female same-sex twins. Additionally, Fu et al. (2002) found 
that antisocial personality disorder explained 62% of the 
genetic correlation between CUD and MDD in a multivari-
ate twin study.
This mixed evidence suggests that the exact nature of 
the relationship between CUD and MDD warrants further 
study. One possibility to comprehensively investigate com-
peting models of co-morbidity is to fit Neale and Kendler’s 
(1995) 13 co-morbidity models, which were based on the 
work of Klein and Riso (1993). Each model and each class 
of models makes different assumptions about the etiologi-
cal mechanisms that lead to the co-morbidity. Four broad 
classes are examined: single liability, independent liability, 
multiformity and correlated liabilities. No other twin model 
approach examines such a large variety of model classes. 
If the co-morbid form arises from a single liability shared 
by CUD and MDD, the diagnostic boundary between MDD 
and CUD may have been artificially drawn, and they could 
be alternate forms of the same disorder. Alternatively, lia-
bility to the co-morbid form may be entirely independent: 
co-morbidity arises due to a third disorder, unrelated to the 
pure forms of MDD and CUD. Multiformity models sug-
gest that the risk factors for CUD and MDD are unrelated, 
but once certain thresholds on the liability of one disorder 
are crossed, the risk of symptoms of the other disorder 
increases sharply. In other words, MDD and CUD influence 
each other in a discontinuous way, only once certain levels 
of risk are reached. In contrast, correlated liabilities mod-
els assume that liabilities between two disorders are related 
continuously, and etiological factors overlap. Any change 
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in risk for one disorder is accompanied by a change in risk 
for the other disorder, whether this is due to shared risk fac-
tors or causality. In addition, the models test whether the 
co-morbidity observed in the population has occurred by 
chance.
The NK comorbidity models have been used to exam-
ine the relationship between a range of other substance-use 
phenotypes (Agrawal et al. 2004, 2007, 2010). Twin mod-
els of co-morbidity would also be a useful tool to study the 
relationship between cannabis involvement and depression 
(Agrawal and Lynskey 2014), as both MDD (e.g. Sullivan 
et al. 2000; Kendler et al. 2006a) and cannabis dependence 
(Lynskey et al. 2002; Verweij et al. 2010) are influenced by 
genetic factors.
To date, no study has examined all 13 models with 
respect to these phenotypes, although previous longitudinal 
and twin studies have produced conflicting findings regard-
ing the relationship between MDD and CUD. Therefore, 
the current study aimed to fit all 13 NK co-morbidity mod-
els to examine the relationship between CUD and MDD 
in a cross-sectional sample of 2410 Australian twins born 
between 1972 and 1979.
Methods
Participants
From a sample of 4131 twin pairs included in the Austral-
ian Twin Registry, 3824 twins and non-twin siblings born 
between 1972 and 1979 were interviewed on cannabis use, 
related drug use and other psychopathology (see Lynskey 
et  al. 2012 for further details of the sample). The analy-
ses presented in this paper were conducted on twins only 
and required complete data from each twin pair for both 
phenotypes. Consequently, 2410 individual twins were 
included in the analysis sample: 565 (396 female, 169 
male) complete MZ pairs and 640 (298 female–female, 118 
male–male and 224 female–male) complete DZ twin pairs. 
The mean age of the sample was 32 years.
Measures
SSAGA‑OZ interview
Computer-assisted telephone interviews based on the 
Australian version of Semi-Structured Assessment of 
the Genetics of Alcoholism (SSAGA-OZ; Bucholz et al. 
1994) were used to assess twins on several variables. The 
SSAGA-OZ has been widely used in family studies of 
alcohol dependence and collects detailed information on 
patterns of DSM-IV (American Psychiatric Association 
2000) symptomatology across a range of mental health 
and substance use disorders. Assessments of these dis-
orders, including MDD and CUD, have been shown to 
have good reliability and validity (Bucholz et  al. 1994). 
In order to keep the measures comparable to current lit-
erature, items were coded as close to DSM-5 (American 
Psychiatric Association 2013) as the available informa-
tion allowed. Although coding the phenotypes as binary 
variables reduces statistical power, the co-morbidity 
models were developed for and can currently only be fit-
ted to binary data.
 Cannabis Use Disorder: Participants were assessed 
on DSM-IV Cannabis Abuse/Dependence criteria. Abuse 
items included “hazardous use”, “social/interpersonal 
problems related to use”, “neglecting major roles to use” 
and “legal problems”. Dependence items included “toler-
ance”, “using larger amounts or using longer”, “repeated 
attempts to quit or control use”, “much time spent using”, 
“physical or physiological problems related to use”, and 
“activities given up to use”. In addition, an assessment 
of cannabis withdrawal was available (see Verweij et  al. 
2013). However, no assessment of “craving”, a crite-
rion introduced in DSM-5, was available for this sample. 
CUD was coded as a binary phenotype. To approximate 
DSM-5 criteria, individuals were coded as 1 (“affected”) 
if they reported at least 2 symptoms of DSM-5 CUD, 
except for “craving”. The remaining participants were 
coded as 0 (“unaffected”), whether or not they reported 
a lifetime history of cannabis use. The “legal problems” 
criterion was removed from DSM-5 and therefore was not 
included in our definition of CUD.
 Major Depressive Disorder: Participants were 
assessed on the following DSM-IV symptoms of 
MDD: “depressed or irritable mood”, “loss of pleas-
ure”, “change in appetite or weight”, “change in sleep”, 
“energy loss or fatigue”, “change in psychomotor activ-
ity”, “feelings of guilt or worthlessness”, “difficulty con-
centrating or making decisions”, and “suicidal ideation”.
MDD was also coded as a binary phenotype. The par-
ticipant was coded as 1 (“affected”) if they experienced 5 
or more of the above symptoms for over 2 weeks, includ-
ing depressed/irritable mood or loss of pleasure. Par-
ticipants were not coded as having MDD if they met the 
following exclusion criteria: (i) their symptoms did not 
affect functioning in any area of life, or (ii) they occurred 
within 2 months of bereavement, (iii) within 1 month of 
using tranquilizers, blood pressure medication or ster-
oids, or (iv) just after having used illegal drugs, alcohol 
or tobacco. As there have been no major changes in the 
diagnostic criteria for MDD between DSM-IV and DSM-
5, the coding was representative of DSM-5 MDD.
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Statistical models
A summary of all models can be found in Table 1. Each 
model makes different assumptions about the way in 
which co-morbid cases arise. A detailed discussion of 
each model can be found in Neale and Kendler (1995) 
and Rhee et al. (2004).
Because both phenotypes were coded as binary vari-
ables, the foundation of each co-morbidity model was a 
normal liability threshold model, which is based on the 
multifactorial theory of inheritance (Falconer 1965).
Similar to widely used liability threshold models, all 
models estimate genetic (A), shared (C) and non-shared 
environmental (E) factors. D was not estimated in the 
current sample, because the difference between MZ and 
DZ correlations indicated an ACE model. However, there 
are several important differences between models:
1. The models differ in the number of liability distribu-
tions they assume. For instance, the Alternate Forms 
model assumes that both phenotypes arise from one 
distribution of liability. In contrast, the Three Inde‑
pendent Disorders model assumes that there are three 
underlying liability distributions. Two of those give 
rise to the pure forms of the phenotypes, and one gives 
rise to the co-morbid form.
2. The models differ in the way in which the above-men-
tioned liabilities produce the phenotype. For example, 
in the Alternate Forms model, an individual develops 
co-morbid CUD and MDD by crossing the threshold 
on the shared liability distribution. However, in the 
Three Independent Disorders model, an individual can 
develop CUD and MDD if they cross the threshold on 
the CUD-specific and MDD-specific distribution at the 
same time, or if they do so on the liability distribution 
for the co-morbid form.
Table 1  Summary and interpretation of Neale and Kendler (1995) models of co-morbidity
Nr. Model Sub-models Description applied to CUD and MDD
1 Alternate forms Single liability: after crossing a common threshold, some develop CUD, 
some MDD. MDD and CUD are alternate forms of the same disorder
2 Three independent disorders Pure forms are unrelated disorders. Three independent liabilities for CUD, 
MDD and co-morbid CUD with MDD
Multiformity The liabilities for CUD and MDD are unrelated. CUD discontinuously 
increases the risk of MDD symptoms, and vice versa when thresholds are 
crossed. Random multiformity assumes one, extreme multiformity two 
thresholds
3 Random multiformity (RM) Assumes a single threshold within one disorder (e.g. CUD), above which 
the risk to develop symptoms of the other disorder (e.g. MDD) suddenly 
increases. This model allows for both disorders to increase the risk of 
symptoms of the respective other
4 RM of MDD Being above the threshold for MDD risk leads to a sudden increase in risk 
for symptoms of CUD, even when below the threshold for CUD
5 RM of CUD Being above the threshold for CUD risk leads to a sudden increase in risk for 
symptoms of MDD, even when below the threshold for MDD
6 Extreme multiformity (EM) There are two distinct thresholds for both disorders. Crossing the 1st thresh-
old leads to the pure form of a disorder. The 2nd threshold allows for indi-
viduals with high amounts of risk factors. Individuals will be at increased 
risk for symptoms if they are above the 2nd threshold (at increased risk) for 
either disorder
7 EM of MDD Being above the 1st threshold for MDD risk only leads to MDD. A propor-
tion of high-risk individuals with MDD (above the 2nd threshold) develop 
CUD symptoms, even when below the 1st threshold for CUD
8 EM of CUD Being above the 1st threshold for CUD risk only leads to CUD. A proportion 
of high-risk individuals with CUD (above the 2nd threshold) have MDD 
symptoms, even when below the 1st threshold for MDD risk
9 Correlated liabilities Correlation between latent genetic and environmental influences on CUD 
and MDD gives rise to co-morbidity
10 Reciprocal causation Liability for CUD has causal influence on liability to experience MDD, and 
vice versa
11 Unidirectional: MDD to CUD Liability to experience MDD has causal influence on liability for CUD
12 Unidirectional: CUD to MDD Liability to experience CUD has causal influence on liability for MDD
13 Chance Co-morbid CUD and MDD occur due to chance alone
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3. One model, the Extreme Multiformity Model, also 
differs from all others in the number of thresholds it 
assumes. Under the assumptions of this model, each 
liability distribution has two thresholds. If an individ-
ual crosses the first threshold, they only develop the 
pure form of a disorder. Crossing the second thresh-
old means that the individual develops the co-morbid 
form. Consequently, co-morbidity arises if an individ-
ual crosses the first threshold on both liability distribu-
tions, the second threshold on one liability distribution 
(e.g. CUD), and/or the other distribution (e.g. MDD).
Data analysis
Data analysis was conducted using OpenMx (Neale et  al. 
2016) for R statistical software (R Core Team 2014). The 
input to each model was a frequency table, which summa-
rized the number of twin pairs fitting into 10 MDD-CUD 
co-morbidity categories (see Table  2). Each twin pair 
member was assigned to one of four disease state catego-
ries: MDD but no CUD (i.e. 1 0), no MDD, but CUD (i.e. 
0 1), both MDD and CUD (i.e. 1 1), and neither (i.e. 0 0). 
Thereafter, twin disease states were combined (i.e. 0 0 
0 1). Although there are 16 different combinations of co-
twin disease states, information about twin order was dis-
regarded to avoid low cell counts. For instance, “0 0 1 0” 
(see Table 2) is a category that contains cases where twin 1 
only (i.e. 1 0 0 0) or twin 2 only (i.e. 0 0 1 0) was affected 
by MDD. Subsuming all replicating disease states resulted 
in ten categories.
For every model, the number of twin pairs expected in 
each of the 10 categories was based on the assumptions of 
the model. Maximum likelihood estimation was used to 
minimize the difference between the observed number of 
cases in each co-morbidity category and the expected num-
ber according to the model. A chi-squared goodness-of-fit 
(χ2) test compared these observed and expected values, and 
indicated model fit. The p value of the χ2 test was used to 
reject models whose predicted data was significantly differ-
ent from the observed data. The best fitting and most parsi-
monious model was chosen based on the Akaike Informa-
tion Criterion (AIC; Akaike 1987). According to Burnham 
and Anderson (2002) an AIC difference of 3 and over indi-
cates that the model with the lower AIC has substantially 
more support.
Results
In the analysis sample, 15.4% (11.9% of females, 22.6% of 
males) met criteria for lifetime CUD and 26.1% (29.5% of 
females, 19.2% of males) met criteria for lifetime MDD. 
Females had a significantly higher prevalence of MDD (OR 
1.77, 95% CI 1.44–2.17) and lower prevalence of CUD 
(OR 0.46, 95% CI 0.37–0.58). CUD was almost twice as 
frequent in individuals with lifetime MDD (24.3%), com-
pared to those without (12.3%). The odds ratio, adjusted for 
sex and age, was 2.66 (95% CI 2.10–3.37).
A conditional logistic regression of MZ twin pairs dis-
cordant for CUD showed that MZ twins with CUD had sig-
nificantly elevated rates of MDD (46.0%) relative to their 
co-twin who did not have CUD (28.12%; OR 2.83, 95% CI 
1.12–7.19; N = 63 MZ pairs).
The model-fitting results are summarized in Table  3. 
In addition to the 13 co-morbidity models, we included a 
saturated model based on twin correlations for comparison. 
Five models can be rejected, due to the large, statistically 
Table 2  Number of twin 
pairs in co-morbidity status 
categories
Used as input for all co-morbidity models
a 0 unaffected
b 1 affected
Twin 1 Twin 2 MZ DZ
MDD CUD MDD CUD
1 0a 0 0 0 298 277
2 0 0 0 1b 28 73
3 0 0 1 0 114 145
4 0 0 1 1 17 35
5 0 1 0 1 16 10
6 0 1 1 0 6 21
7 0 1 1 1 16 23
8 1 0 1 0 47 33
9 1 0 1 1 12 18
10 1 1 1 1 11 5
Total 565 640
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significant differences between the observed cell counts 
within the co-morbidity categories (see Table  2) and the 
cell counts expected under the model: the Chance, Alter‑
nate Forms, Three Independent Disorders, RM of MDD, 
and EM of MDD models.
The only models that do not have substantially less sup-
port than the saturated model (i.e. an AIC difference larger 
than 3) are the RM of CUD (model 5) and CUD causes 
MDD (model 12) models (see Fig. 1a, b), with differences 
of 2.30 and 2.34 respectively. Both models have substan-
tially more support than the Correlated Liabilities model.
These two best fitting models are, however, not sub-
stantially different from some of the models within their 
class. The RM of CUD model is not substantially dif-
ferent from the Random Multiformity model. The CUD 
causes MDD model is not substantially different from 
the MDD causes CUD and Reciprocal Causation model. 
Additionally, both models do not substantially differ from 
the Extreme Multiformity model.
In the best fitting models both CUD and MDD are 
influenced by genetic and non-shared environmental fac-
tors. In the case of CUD, 79–80% of the total variance is 
estimated to be explained by genetic factors and 20–21% 
by non-shared environmental factors. For MDD, 43–48% 
of the total variance is explained by genetic, 52–57% by 
non-shared environmental factors. Model-fit did not sig-
nificantly deteriorate when C was dropped from both 
models. Parameter estimates from all models can be 
found in Table 4.
Table 3  Co-morbidity model fit statistics and questions models aim to address
Model Question χ2 Df p AIC
Saturated Model 13.16 11 0.283 −8.84
 1 Alternate Forms Alternate forms of the same disorder? 96.31 14 <0.001 68.31
 2 Three Indep. Disorders Co-morbid form is an independent disorder? 32.90 8 <0.001 16.90
 3 Random Multiformity Abruptly increase symptoms of each other? 15.10 10 0.129 −4.90
 4 RM of MDD MDD abruptly increases CUD symptoms? 27.04 11 0.004 5.04
 5 RM of CUD CUD abruptly increases MDD symptoms? 15.46 11 0.162 −6.54
 6 Extreme Multiformity Abruptly increase symptoms of each other in extreme cases? 16.32 10 0.091 −3.68
 7 EM of MDD MDD abruptly increases CUD symptoms in extreme cases? 28.23 11 0.003 6.23
 8 EM of CUD CUD abruptly increases MDD symptoms in extreme cases? 19.50 11 0.053 −2.50
 9 Correlated Liabilities Liabilities are correlated? 15.21 9 0.085 −2.79
 10 Reciprocal Causation CUD and MDD cause each other? 15.23 10 0.124 −4.77
 11 MDD causes CUD MDD causes CUD? 17.86 11 0.085 −4.14
 12 CUD causes MDD CUD causes MDD? 15.50 11 0.161 −6.50
 13 Chance Co-morbid due to chance? 59.46 12 <0.001 35.46
Fig. 1  Parameter estimates from best fitting co-morbidity models: a Random Multiformity of CUD, b Causation—CUD causes MDD. r prob-
ability of MDD phenotype if above threshold on CUD liability, iCUD regression coefficient, *Significant at the 0.05 level
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Discussion
To our knowledge, this study is the first to fit the 13 co-
morbidity models proposed by Neale and Kendler (1995) to 
cannabis use disorder and major depressive disorder. Both 
epidemiological and discordant twin analyses confirmed 
that these models were appropriate for the current sample. 
In line with other cross-sectional studies (see e.g. Degen-
hardt et  al. 2012) epidemiological analyses showed that 
CUD and MDD were significantly co-morbid. Discord-
ant twin analyses, which will be discussed further below, 
showed that causal processes could not be excluded as an 
explanation for this co-morbidity, because MZ twins with 
CUD were significantly more likely to display symptoms 
of MDD than their co-twin without CUD. Therefore, there 
was sufficient reason to further explore causality in the co-
morbidity model analyses.
The two best-fitting models were Random Multiformity 
of CUD and CUD causes MDD. Both models fit substan-
tially better than the Correlated Liabilities model, and not 
substantially worse than the Saturated model. In addition, 
five models could be statistically rejected: the Alternate 
Forms, Chance, Three Independent Disorders, RM of MDD 
and EM of MDD models. The heritability estimates in the 
best fitting models range from 79 to 80% for CUD and 43 
to 49% for MDD.
Model-fitting
These model-fitting results suggest that the direction of 
effect goes from CUD to MDD. Firstly, both RM of MDD 
and EM of MDD can be statistically rejected. It seems plau-
sible, therefore, that the fit of the bi-directional Random 
Multiformity and Extreme Multiformity models is driven 
by the paths they have in common with RM of CUD and 
EM of CUD, respectively. Secondly, the CUD causes MDD 
fits better than the MDD causes CUD model. Although 
this difference is not substantial, the fit of the MDD causes 
CUD model may reflect that Direction of Causation mod-
els are difficult to distinguish when modes of inheritance 
of the disorders are similar (Heath et al. 1993). In the cur-
rent study, this may be because both disorders are mainly 
influenced by A and E, rather than by different etiologi-
cal factors (e.g. A C E vs. A E). Lastly, the MDD causes 
CUD model, along with all other models with a direction 
of effect from MDD to CUD, was a substantially poorer fit 
than the Saturated Model.
It is unclear, however, which of the two best-fitting 
models is more likely. The CUD causes MDD model 
assumes that the liability to develop MDD symptoms 
increases continuously, as the risk of CUD increases. The 
threshold in this model does not equal a sudden increase 
in risk, which means that even sub-threshold increases in 
liability to CUD have a causal influence on the liability 
to develop MDD (Rhee et  al. 2004). On the other hand, 
the RM of CUD model assumes that the risk of MDD 
symptoms increases discontinuously, once the threshold 
on the CUD liability has been passed (i.e. an individual 
has reached a liability high enough to develop the disor-
der). An additional difference between the models is their 
assumption about etiological processes. The causal model 
assumes that any causal processes occur at the level of 
the liability (Rhee et  al. 2004), while the RM models 
remain agnostic about the way in which one disorder 
leads to symptoms of the other.
Despite some differences, the RM of CUD and CUD 
causes MDD models are not incompatible. Causality may 
play a role, and the good fit of the RM of CUD model may 
indicate that the causal influences on the risk of MDD 
only occur at higher levels of CUD risk (i.e. post-thresh-
old). Additionally, it is likely that there are shared etio-
logical factors between CUD and MDD. Evidence from 
twin (Fu et al. 2002; Lynskey et al. 2004) and molecular 
genetic studies (Bobadilla et al. 2013; Sherva et al. 2016; 
Hodgson et al. 2016) suggests that there are genetic fac-
tors influencing both cannabis involvement and MDD. 
There is also a plethora of environmental factors that 
act as risk factors for both (e.g. Fergusson and Horwood 
1997; Feingold et al. 2014). Overall, the almost identical 
fit of both models may indicate that there are threshold-
dependent causal links from CUD to MDD, which occur 
at the level of liability.
This interpretation is compatible with several find-
ings. Risk factors for CUD, such as heavy cannabis use, 
are likely to exert an environmental and genetic effect 
on MDD. Heavy cannabis use can alter various domains 
of cognitive functioning, such as attention and memory 
(Solowij 2002), and thereby affect daily functioning and 
potentially create circumstances in which individuals are 
more likely to develop MDD. For instance, cannabis use 
impacts negatively on educational attainment (Lynskey 
and Hall 2000), which in turn may affect emotional well-
being. Environmental effects may also manifest them-
selves through changes in brain structure and function. 
Heavy cannabis users show a decrease in amygdala vol-
umes (Yucel et  al. 2008), which is also the case in un-
medicated patients with MDD (Hamilton et  al. 2008). 
Furthermore, the endocannabinoid system, primary site 
of the neurochemical effects of cannabis, is thought to be 
involved in mood regulation (Ashton and Moore 2011). 
Genes may modulate these environmental influences. 
Lastly, the conclusion that causal processes may be at 
work in individuals at high risk for CUD (e.g. high lev-
els of cannabis use), also fits well with longitudinal stud-
ies which show that high levels of cannabis use are more 
strongly associated with MDD than lower levels.
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Heritability estimates
The heritability estimates obtained from the models are 
similar to other twin studies for MDD (Sullivan et  al. 
2000; Kendler et  al. 2006b), and to studies on cannabis 
abuse/dependence that included similar samples. Kendler 
et  al. (2006a) report a heritability estimate of 77% (95% 
CI 46–93%) for DSM-IV cannabis abuse/dependence in a 
sample of same-sex and opposite-sex twins with a mean 
age of 28.2. While a meta-analysis on twin studies report-
ing at least 1 symptom of abuse/dependence, presents lower 
heritability estimates [males: 54.4% (95% CI 37.9–64.9%), 
females: 58.5 (95% CI 44.2%–72.9%), Verweij et al. 2010], 
the higher estimate obtained in the current may be related 
to differences in sampling or the definition of problematic 
cannabis use.
Limitations and future research
Difficulties in differentiating between models were a known 
limitation, based on previous studies. Rhee et  al. (2004) 
provide a detailed discussion of general limitations of the 
NK model fitting approach. Although Rhee et  al. (2004) 
demonstrated that the NK approach to discriminating 
between different models of co-morbidity is valid; they 
did so with a large simulated sample and still noted several 
challenges. They highlighted that it is particularly difficult 
to discriminate between the multiformity and the correlated 
liabilities model classes, which was also the case in the 
current sample. Additionally, Rhee et al. (2004) pointed out 
that discrimination within subclasses of models (e.g. RM 
vs. RM of CUD) is also problematic. In the current analy-
ses, the difference within subclasses was often not more 
than 3 AIC. It may be beneficial to replicate the study with 
larger samples or use meta-analysis to examine whether 
differences between models become more distinct. Replica-
tion of our results would be useful to explore whether the 
results of the current study are cohort-specific or generalize 
across cohorts, but is outside the scope of the present study.
One limitation of the current study is that sex differ-
ences have not been taken into account. The prevalence of 
MDD and CUD did differ between males and females in 
the analysis sample, but currently all co-morbidity models 
can only be fitted on contingency tables, in which it was 
not possible to specify separate thresholds for males and 
females. The alternative approach of fitting separate mod-
els for males and females was not feasible due to lack of 
power. However, there are currently no grounds to assume 
that different co-morbidity models would explain co-mor-
bid cases in males and females. For instance, Agrawal 
et al. (2010) examined the co-morbidity between cannabis 
and tobacco use, and fitted separate models for male and 
female twins. They found that model fits were very similar 
for both sexes. It may be an interesting avenue for future 
research to explore sex differences in larger samples or 
using meta-analysis.
Given that one of the best-fitting models makes assump-
tions about causality, it is also an important limitation that 
the data are retrospective and age of onset was not consid-
ered in the analyses. Using retrospective data has several 
disadvantages (see e.g. Coughlin 1990), but for the current 
analyses the most pertinent drawback is that longitudinal 
data would be better suited to test direction of causation. 
Beyond twin models, recent molecular genetic methods 
also offer an interesting avenue to assess causality (see 
Pickrell et al. 2016).
Finally, the discordant twin results are difficult to inter-
pret due to the small number of MZ twin pairs discordant 
for CUD. The results are in contrast to study results in Lyn-
skey et al. (2004) and in line with those in Lin et al. (1996), 
but overall they are not entirely comparable to either: both 
studies examined cannabis dependence rather than CUD. 
To conclusively examine whether causal processes can be 
excluded using the discordant twin method, larger sample 
sizes would be necessary. However, for the purposes of 
the current study, the main intention was establishing that 
causal processes could not be ruled out within the current 
data set.
A valuable next step would be the inclusion of known 
confounding factors. As mentioned above, Fu et al. (2002) 
have found that antisocial personality disorder, while 
being comparatively rare (Coid et  al. 2006) and therefore 
unlikely to explain most co-morbid cases, is a significant 
confounder in the genetic relationship between cannabis 
dependence and MDD. Moreover, longitudinal studies have 
highlighted that cannabis users and non-users differ on a 
number of domains (Fergusson and Horwood 1997; Fein-
gold et al. 2014). As such, it would be valuable to examine 
which models provide the best fit when confounding factors 
are included.
Conclusion
Overall, the model fitting approach has been a benefi-
cial indicator of the likely relationship between CUD and 
MDD. While it was not possible to statistically differenti-
ate between the two best fitting models RM of CUD and 
CUD causes MDD, they both seem to indicate that the 
direction of influence goes from CUD to MDD. Combined, 
the models suggest that CUD risk factors may cause MDD 
symptoms, but only in higher risk individuals. In addi-
tion, several models can be statistically excluded: CUD 
and MDD are not likely to be co-morbid by chance, arise 
from the same risk factors, or be due to a liability separate 
from the pure form of the disorders. The fact that a Random 
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Multiformity model is the best fitting model is remarkable, 
because this model is not widely reported. Replications on 
larger samples would be beneficial in order to help differen-
tiate between models with subtle differences.
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